Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07330778 · ClinicalTrials.gov registry record · Phase 1
A Study of CDX-622 in Participants With Mild to Moderate Asthma
A Phase 1 study of Mild to Moderate Asthma, sponsored by Celldex Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT07330778: Recruiting Phase 1 study of Mild to Moderate Asthma, sponsored by Celldex Therapeutics.
NCT07330778 is a Phase 1 study of Mild to Moderate Asthma that is actively recruiting participants, run by Celldex Therapeutics. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07330778, a Phase 1 study of Mild to Moderate Asthma, is actively recruiting participants, sponsored by Celldex Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
Primary Outcome
Occurrence and incidence of Treatment-Emergent Adverse Events (TEAE) and serious adverse events during the study.
Conditions Studied
Interventions
- DRUG CDX-622
Study Locations (1)
Kansas
- The University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
What NCT07330778 shows while recruiting
NCT07330778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Mild to Moderate Asthma appearing as the primary indexed condition, and to 1 intervention - of which CDX-622 is the first listed.
NCT07330778 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT07330778 about?
NCT07330778 is a clinical study titled "A Study of CDX-622 in Participants With Mild to Moderate Asthma". This is a study to determine the safety, pharmacodynamics (PD), and pharmacokinetics (PK) of CDX-622 in adults with mild to moderate asthma.
What is the current status of trial NCT07330778?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02. Estimated completion is 2027-03.
What conditions does trial NCT07330778 study?
This clinical trial studies the following conditions: Mild to Moderate Asthma.
What interventions are being tested in trial NCT07330778?
The interventions under investigation include: CDX-622 (DRUG).
Who is sponsoring clinical trial NCT07330778?
This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07330778 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07330778's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia